The National Multiple Sclerosis Society (NMSS) has officially announced its collaboration with Corrona on the launch of the Corrona Multiple Sclerosis Registry to compare the safety and effectiveness of approved therapies in multiple sclerosis (MS).
Corrona, based in Cambridge, Massachusetts, conducts observational cohort studies, offering analytic expertise for longitudinal clinical data, patient-reported measures and others to compare effectiveness, post-market safety reporting and commercial applications.
Under the accord, a national observational registry will collect and analyze longitudinal outcomes associated with several MS therapies. The registry, which has already enrolled its first patient, eventually plans to recruit 5,000 people with MS.
Today, MS is managed through disease-modifying treatments that prevent relapses and exacerbations, slowing its progression.
Since the U.S. Food and Drug Administration approved the first MS disease-modifying treatment in 1993, patients have seen an “an unprecedented leap forward” in the number and variety of medications available, Daniel Kantor, founding president of the Medical Partnerships 4 MS, said in a press release. “But MS research in the U.S. lags behind other fields in collecting reliable real-world data to compare the safety and effectiveness” of these therapies, he said.
The registry will collect data from patients and their treating neurologists through questionnaires, and includes physician assessments and patient-reported outcomes. Along with the NMSS and other partners, Corrona’s team of biostatisticians and epidemiologists will study the comparative safety and efficacy of approved MS therapies.
“Identifying the optimal treatment strategy is a critical issue for people with MS and their healthcare providers,” said Bruce Bebo, executive vice president of research at NMSS. “The collaboration with Corrona on the MS registry addresses this challenge and furthers our goal of ensuring that people with MS have [the] information, tools and resources to live their best lives.”
This is Corrona’s sixth registry, following studies in rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and others.
“Corrona is honored to partner with the National MS Society and U.S. neurologists to create a national MS registry that can help guide treatment decisions for patients based on real-word comparative effectiveness and safety analyses,” said Jeff Greenberg, chief scientific officer of Corrona.
To learn more about the Corrona MS Registry and enrollment details, contact email@example.com or call (508) 408-5398.